Despite the stagnant biotech IPO market of the last six months, LB Pharmaceuticals has set out plans to reel in hundreds of millions of dollars through its upcoming public debut. The ...

As COVID-19 cases continue to rise across the United States, scientists are monitoring the spread of a new variant called LB.1. The highly contagious omicron subvariant, along with the fast-growing ...

After a promising start, biotech IPOs all but fizzled out this year, but LB Pharmaceuticals is hoping that won't stymy its chances of completing a Nasdaq listing. New York-based LB is hoping to raise ...

There are no signs so far that the new LB.1 variant is causing more severe disease in COVID-19 patients, the Centers for Disease Control and Prevention says, as infections have begun to accelerate in ...